Endologix (NASDAQ:ELGX) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday.
A number of other brokerages have also weighed in on ELGX. Piper Jaffray Companies reiterated an “overweight” rating on shares of Endologix in a research report on Tuesday, December 12th. Royal Bank of Canada cut their target price on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 8th. Canaccord Genuity reiterated a “hold” rating and set a $5.00 target price on shares of Endologix in a research report on Monday, October 9th. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the stock a “hold” rating in a research report on Friday, October 6th. Finally, JPMorgan Chase & Co. lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. Endologix currently has a consensus rating of “Hold” and a consensus price target of $5.41.
Endologix (NASDAQ:ELGX) opened at $4.36 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61. The firm has a market cap of $356.35, a PE ratio of -4.69 and a beta of 0.72. Endologix has a 1 year low of $4.08 and a 1 year high of $7.66.
Institutional investors have recently made changes to their positions in the company. Kopp Investment Advisors LLC lifted its holdings in shares of Endologix by 11.5% in the second quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 2,270 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Endologix in the second quarter worth about $111,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Endologix in the second quarter worth about $142,000. Valeo Financial Advisors LLC purchased a new stake in shares of Endologix in the third quarter worth about $163,000. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Endologix by 128.1% in the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock worth $170,000 after buying an additional 19,600 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3148507/endologix-elgx-lowered-to-sell-at-bidaskclub.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.